Rezolute (RZLT) Accounts Payables (2011 - 2026)
Rezolute recorded quarterly Accounts Payables of $3.2 million in Q1 2026, down 15.54% quarter-over-quarter from $3.8 million in Q4 2025, and down 50.86% year-over-year from $6.5 million in Q1 2025.
Rezolute's Accounts Payables history runs 16 years deep, the most recent figure standing at $3.2 million for Q1 2026.
- In Q1 2026, Accounts Payables fell 50.86% year-over-year to $3.2 million; the TTM figure through Mar 2026 stood at $3.2 million (down 50.86% YoY), while the FY2025 annual figure was $5.8 million, up 18.53% from the prior year.
- Accounts Payables came in at $3.2 million for Q1 2026 at Rezolute, down from $3.8 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $6.5 million in Q1 2025 to a low of $1.1 million in Q3 2022.
- A 5-year average of $3.2 million and a median of $3.2 million in 2026 frame the typical range for Accounts Payables.
- Across the five-year window, Accounts Payables surged 188.78% in 2023 and slumped 50.86% in 2026, its largest moves.
- Rezolute's Accounts Payables stood at $2.8 million in 2022, then gained by 26.47% to $3.6 million in 2023, then declined by 12.36% to $3.1 million in 2024, then rose by 20.13% to $3.8 million in 2025, then dropped by 15.54% to $3.2 million in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $3.2 million, $3.8 million, and $3.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.05 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 83.00 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 10.62 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 8.64 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 489.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.03 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 126.63 Mn |
| 10 | Rezolute | 374.41 Mn | 374.41 Mn | - | 3.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.20 Mn |
| Dec 31, 2025 | 3.78 Mn |
| Sep 30, 2025 | 3.26 Mn |
| Jun 30, 2025 | 5.81 Mn |
| Mar 31, 2025 | 6.50 Mn |
| Dec 31, 2024 | 3.15 Mn |
| Sep 30, 2024 | 2.18 Mn |
| Jun 30, 2024 | 4.90 Mn |
| Mar 31, 2024 | 3.50 Mn |
| Dec 31, 2023 | 3.59 Mn |
| Sep 30, 2023 | 2.43 Mn |
| Jun 30, 2023 | 3.27 Mn |
| Mar 31, 2023 | 2.95 Mn |
| Dec 31, 2022 | 2.84 Mn |
| Sep 30, 2022 | 1.11 Mn |
| Jun 30, 2022 | 1.13 Mn |
| Mar 31, 2022 | 1.56 Mn |
| Dec 31, 2021 | 4.35 Mn |
| Sep 30, 2021 | 1.59 Mn |
| Jun 30, 2021 | 1.04 Mn |
| Mar 31, 2021 | 811,000.00 |
| Dec 31, 2020 | 612,000.00 |
| Sep 30, 2020 | 797,000.00 |
| Jun 30, 2020 | 893,000.00 |
| Mar 31, 2020 | 1.26 Mn |
| Dec 31, 2019 | 1.25 Mn |
| Sep 30, 2019 | 1.32 Mn |
| Jun 30, 2019 | 563,000.00 |
| Mar 31, 2019 | 954,277.00 |
| Dec 31, 2018 | 2.09 Mn |
| Sep 30, 2018 | 1.79 Mn |
| Jun 30, 2018 | 1.85 Mn |
| Mar 31, 2018 | 25,046.00 |
| Dec 31, 2017 | 2.12 Mn |
| Sep 30, 2017 | 1.57 Mn |
| Jun 30, 2017 | 951,239.00 |
| Mar 31, 2017 | 1.89 Mn |
| Dec 31, 2016 | 1.53 Mn |
| Sep 30, 2016 | 1.29 Mn |
| Mar 31, 2016 | 2.17 Mn |
| Dec 31, 2015 | 2.22 Mn |
| Sep 30, 2015 | 1.67 Mn |
| Jun 30, 2015 | 1.41 Mn |
| Mar 31, 2015 | 1.33 Mn |
| Dec 31, 2014 | 874,700.00 |
| Sep 30, 2014 | 320,114.00 |
| Jun 30, 2014 | 460,311.00 |
| Mar 31, 2014 | 645,696.00 |
| Dec 31, 2013 | 477,496.00 |
| Sep 30, 2013 | 408,884.00 |
| Jun 30, 2013 | 188,346.00 |
| Mar 31, 2013 | 252,436.00 |
| Dec 31, 2012 | 8,602.00 |
| Sep 30, 2012 | 15,643.00 |
| Jun 30, 2012 | 107,022.00 |
| Mar 31, 2012 | 8,852.00 |
| Dec 31, 2011 | 186,764.00 |
| Sep 30, 2011 | 5,499.00 |
| Jun 30, 2011 | 11,657.00 |